ArticleAmerican journal of physiology. Regulatory, integrative and comparative physiology2024
Zinc-chelating BET bromodomain inhibitors equally target islet endocrine cell types.
Rachel A Jones Lipinski, Jennifer S Stancill, Raymundo Nuñez, Sarah L Wynia-Smith, Daniel J Sprague, Joshua A Nord, Amir Bird, John A Corbett, Brian C Smith
Open access · greenAbstract read
In one paragraphArticle in American journal of physiology. Regulatory, integrative and comparative physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors at 2 institutions in 1 country.
Rachel A Jones LipinskiDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.ORCID 0000-0003-4586-0445 Jennifer S StancillDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.
Raymundo NuñezDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.
Sarah L Wynia-SmithDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.
Daniel J SpragueProgram in Chemical Biology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.ORCID 0000-0002-0709-3284 Joshua A NordDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.
Amir BirdDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.
John A CorbettDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.ORCID 0000-0002-1134-4664 Brian C SmithDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.ORCID 0000-0001-6330-2768 Medical College of Wisconsin · USMedical University of South Carolina · US
Funding
BIOCHEMICAL MECHANISM OF BETA-CELL DESTRUCTIONR01DK052194 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CORBETT, JOHN A · 1998 to 2025
$8.8MMECHANISMS OF VIRAL INDUCED BETA CELL DAMAGER01AI044458 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CORBETT, JOHN A · 1998 to 2024
$7.5MTraining in Signature Transdisciplinary Cardiovascular SciencesT32HL134643 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Justin L Grobe, Jacquelyn P Kulinski · 2017 to 2026
$4.2MBiochemical mechanisms of beta cell protection through bromodomain inhibitionR01DK119359 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI Brian Christopher Smith · 2018 to 2026
$3.1MProtective Mechanisms in Pancreatic Beta-cellsK99DK129709 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI STANCILL, JENNIFER SUSAN · 2021 to 2022
$180kBreakthrough T1D 3-PDF-2023-1321-A-NNHLBI NIH HHS T32 HL134643NIAID NIH HHS R01 AI044458NIDDK NIH HHS K99 DK129709NIDDK NIH HHS R01 DK052194NIDDK NIH HHS R01 DK119359
6 · The paper itselfAbstract
Inhibition of the bromodomain and extraterminal domain (BET) protein family is a potential strategy to prevent and treat diabetes; however, the clinical use of BET bromodomain inhibitors (BETis) is associated with adverse effects. Here, we explore a strategy for targeting BETis to β cells by exploiting the high-zinc (Zn
Indexed as
Bromodomain Containing ProteinsChelating AgentsInsulin-Secreting CellsZincAnimalsAzepinesGlucagon-Secreting CellsHumansMaleMiceMice, Inbred C57BLNuclear ProteinsTranscription FactorsTriazolesAzepinesBrd4 protein, mouseBromodomain Containing ProteinsChelating Agents(+)-JQ1 compoundNuclear ProteinsTranscription FactorsTriazolesZincchemical biologyendocrine cellsepigeneticsisletzinc
Identifiers
PMID38618911
PMCPMC11381023
OpenAlexW4394813996
What OpenQuestion holds
Textmetadata
Read underepoch 390